Clinical Trials | December 08, 2025
Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors
HYMPAVZI’s safety profile was generally favorable
HYMPAVZI’s safety profile was generally favorable
Demonstrate significant bleed reduction in hemophilia A and B
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Subscribe To Our Newsletter & Stay Updated
